SCHEMBL6684977

SCHEMBL6684977

CCC1OC(=O)N(Cc2cccc(NC(=O)c3ccno3)c2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.43
PDE4A P27815 9/20 0.43
PDE4B Q07343 9/20 0.43
PDE4C Q08493 9/20 0.43
ACKR3 P25106 2/20 0.43
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
MET P08581 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
PARP1 P09874 1/20 0.41
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
F2RL3 Q96RI0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8520971 0.92 PDE4A (0.41) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6687195 0.92 PDE4A (0.48) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6692324 0.91 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6656438 0.89 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6654394 0.89 TSHR (0.49) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6684488 0.88 PDE4D (0.45) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6653612 0.88 KDM4E (0.49) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6657995 0.88 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6685270 0.87 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6687865 0.87 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.